Summary of Evidence

Chuong Ho; Carolyn Spry

Warning: The NCBI web site requires JavaScript to function. more...

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ho C, Spry C. Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May 17.

Cover of Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines

Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines [Internet].

Show details

Contents

< Prev Next >

Summary of Evidence

Quantity of Research Available

A total of 147 citations were identified in the literature search. Following screening of titles and abstracts, 136 citations were excluded and 11 potentially relevant reports from the electronic search were retrieved for full-text review. No potentially relevant publication was retrieved from the grey literature search. Of these potentially relevant articles, no publication met the inclusion criteria to be included in this report. Appendix 1 describes the PRISMA flowchart of the study selection.

Summary of Findings

What is the clinical effectiveness regarding the use of rituximab for patients with GPA and MPA to maintain remission?

No evidence was found on the clinical effectiveness regarding the use of rituximab for patients with GPA MPA to maintain remission.

What is the cost-effectiveness regarding the use of rituximab for patients with GPA and MPA) to maintain remission?

No evidence was found on the cost-effectiveness regarding the use of rituximab for patients with GPA and MPA to maintain remission.

What are the evidence-based guidelines regarding the use of rituximab, including dosing strategies, for patients with GPA and MPA?

No evidence was found on the evidence-based guidelines regarding the use of rituximab for patients with GPA and MPA.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK481993

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Ho C, Spry C. Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May 17. Summary of Evidence.
PDF version of this title (273K)

Summary of Evidence - Rituximab for Granulomatosis with Polyangiitis or Microsco...
Summary of Evidence - Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines [Internet].

Summary of Evidence

Quantity of Research Available

Summary of Findings

Views

In this Page

Other titles in this collection

Recent Activity